Guardant Health, Inc.
NASDAQ:GHMedical - Diagnostics & Research
+$2.67 today
- Market cap
- $19.64B
- Beta
- 1.62
- P/E (TTM)
- -39.9
- EPS (TTM)
- -$3.30
Volume 1.50M
Average 2.21M
GH EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Guardant Health, Inc.NASDAQ: GH
EBITDA · Q3 FY2026 · quarter ended Sep 2026
EBITDA remains negative
Q3 FY2026 EBITDA was -$112.5M, compared with -$82.24M a year earlier. Trailing-twelve-month EBITDA was -$441.45M.
Context
- EBITDA amounted to 38.1% of revenue in FY2025, down 14.7 pp from a year earlier.
- EBITDA grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 19 analysts of -$366.94M (+1.9%) for the fiscal year ending Dec 2026, a slowdown from the +4.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$112.5M-3.2% QoQ
- Last fiscal yearDec 2025
- -$373.91M+4.2% YoY
- LTMSep 2026
- -$441.45M-24.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -36.8% | +26.3% | +63.1 pp |
| 1 year | +4.2% | +1.9% | -2.3 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (373.91M) USD
- Year-over-year change
- +4.2%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (373.91M) | +4.2% |
| FY2024 | 2024-12-31 | (390.12M) | +10.0% |
| FY2023 | 2023-12-31 | (433.31M) | +29.5% |
| FY2022 | 2022-12-31 | (614.91M) | -71.0% |
| FY2021 | 2021-12-31 | (359.62M) | — |
EBITDA vs competitors
How GH compares with its peers on the latest reported figures
- GH's LTM Sep 2026 EBITDA of -$441.45M is the lowest of the 10 companies compared; the peer median is -$58.51M.
- Its year-over-year change of -24.7% is the 7th highest of 10, against a peer median of +10.8%.
- EBITDA amounts to 34.5% of revenue for GH, versus a peer median of 18.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
BLLNBillionToOne, Inc. | LTM Jun 2026 | $50.25M | +362.6% | — | 12.6% |
| LTM Jun 2026 | $12.89M | +145.3% | — | 1.7% | |
| LTM Mar 2026 | -$725.67K | -101.8% | — | 0.2% | |
| LTM Mar 2026 | -$18.34M | +33.2% | — | 19.1% | |
| LTM Mar 2026 | -$58.51M | -133.4% | — | 18.3% | |
| LTM Mar 2026 | -$85.53M | -16.7% | — | 132.6% | |
| LTM Jun 2026 | -$178.71M | +15.6% | — | 6.6% | |
| LTM Mar 2026 | -$334.2M | -423.0% | — | 40.3% | |
| LTM Jun 2026 | -$374.1M | +10.8% | — | 226.4% | |
| LTM Sep 2026 | -$441.45M | -24.7% | — | 34.5% | |
| Peer median (excluding GH) | -$58.51M | +10.8% | — | 18.3% | |
Competitors are the stored peer set for GH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 373.65M | 449.54M | 563.95M | 739.02M | 982.02M |
| Cost of Revenue | 122.91M | 156.33M | 227.05M | 289.8M | 349.01M |
| Gross Profit | 250.74M | 293.21M | 336.9M | 449.22M | 633.01M |
| Gross Margin | 67.1% | 65.2% | 59.7% | 60.8% | 64.5% |
| Research & Development | 263.22M | 373.81M | 367.19M | 347.75M | 364.19M |
| Selling, General & Admin | 398.52M | 463.78M | 451.03M | 545.06M | 706.07M |
| Operating Expenses | 661.74M | 837.59M | 901.62M | 892.81M | 1.07B |
| Depreciation & Amortization | 22.27M | 35.96M | 42.88M | 42.39M | 39.74M |
| EBITDA | (359.62M) | (614.91M) | (433.31M) | (390.12M) | (373.91M) |
| EBITDA Margin | -96.2% | -136.8% | -76.8% | -52.8% | -38.1% |
| Operating Income | (411M) | (544.38M) | (564.73M) | (443.59M) | (437.25M) |
| Operating Margin | -110.0% | -121.1% | -100.1% | -60.0% | -44.5% |
| Interest Income | 3.93M | 6.07M | 35.37M | 53.69M | 34.1M |
| Interest Expense | 2.58M | 2.58M | 2.58M | 2.58M | 3.9M |
| Other Income / Expenses | 26.53M | (109.07M) | 85.96M | 8.51M | 19.71M |
| Income Before Tax | (384.47M) | (653.45M) | (478.76M) | (435.09M) | (417.54M) |
| Pre-Tax Margin | -102.9% | -145.4% | -84.9% | -58.9% | -42.5% |
| Income Tax Expense | 300K | 1.14M | 685K | 1.28M | (1.26M) |
| Net Income | (405.67M) | (654.59M) | (479.45M) | (436.37M) | (416.28M) |
| Net Margin | -108.6% | -145.6% | -85.0% | -59.0% | -42.4% |
| EPS (Basic) | (4.00) | (6.41) | (4.28) | (3.56) | (3.32) |
| EPS (Diluted) | (4.00) | (6.41) | (4.28) | (3.56) | (3.32) |
| Weighted Avg Shares | 101.31M | 102.18M | 111.99M | 122.75M | 125.37M |
| Weighted Avg Shares (Diluted) | 101.31M | 102.18M | 111.99M | 122.75M | 125.37M |
Guardant Health, Inc.
NASDAQ:GH
Intrinsic Alpha fair value
Locked
Current Price
$145.14
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.